



ACARIX SECURES INSURANCE COVERAGE IN TEXAS AND RECEIVES FIRST CADSCOR®SYSTEM ORDER

Acarix, a leader in acoustic and AI-based cardiac diagnostics, confirms insurance coverage for the CADScor®System by key payors in Texas, considered the largest medical device market in the US. As a result, Acarix received first order of CADScor®System from a leading heart center in Texas, with additional orders expected from the region in early 2023.

The Acarix CADScor®System has since its CPT III reimbursement code was activated in July 2022 secured insurance coverage by commercial payors and Medicare across key regions in the US. Texas is considered the largest medical device market in the US with nearly 30 million inhabitants and Houston is home to the largest medical center in the world. With high volumes of patients with chest pains and risks of Coronary Artery Disease, there is a need for rapid cardiac diagnostics.

“Distinguishing between serious and benign chest pain is imperative, and tools to rule out serious disease are useful to streamline and expedite care in an overburdened healthcare system,” commented Dr. Farhan Ali, MD, MA, MPH, FACC, FSCAI, RPVI, and President of the Heart Center of North Texas. “The CADScor®System is a valuable addition to our diagnostic workflow because it can be used on symptomatic patients as a first-line diagnostic aid to rule out coronary artery disease in low-risk patients quickly.”

“Adding Texas to the states where the CADScor®System is now available for chest pain patients is an important step forward for Acarix as we expand across the US. We are very pleased to secure payments levels from additional strategic payors and glad to have The Heart Center of North Texas as the first local clinic offering the CADScor®System as a first-line diagnostic aid for patients experiencing chest pains”, stated Helen Ljungdahl Round, Acarix President and CEO.

The Acarix CADScor®System is an acoustic and AI-based solution to rapidly and non-invasively evaluate patients with chest pains in 10 minutes. Its CPT-III code became effective in July 2022, and clinics are now receiving reimbursement payments from US insurance companies.

For more information contact:

Helen Ljungdahl Round, CEO, phone +1 267 809 1225, +46 730 770283, email helen.round@acarix.com

Christian Lindholm, CFO, phone +46 705 118333, email christian.lindholm@acarix.com



About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor®System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se) is Certified Advisor of Acarix. For more information, please visit www.acarix.com.

Attachments

[Acarix secures insurance coverage in Texas and receives first CADScor®System order](#)